REFERENCES
- Craft E, Abu-Qare A, Flaherty M, Garofolo M, Rincavage H, Abou-Donia M. Depleted and natural uranium: chemistry and toxicological effects. J Toxicol Environ Health B Crit Rev 2004; 7(4)297–317
- Moulin C, Laszak I, Moulin V, Tondre C. Time-resolved laser-induced fluorescence as a unique tool for low-level uranium speciation. Appl Spectrosc 1998; 52(4)528–535
- Muller D, Houpert P, Cambar J, Henge-Napoli MH. Role of the sodium-dependent phosphate c-transporters and of the phosphate complexes of uranyl in the cytotoxicity of uranium in LLC-PK1 cells. Toxicol Appl Pharmacol 2006; 214(2)166–177
- Vidaud C, Dedieu A, Basset C, Plantevin S, Dany I, Pible O, Quemeneur E. Screening of human serum proteins for uranium binding. Chem Res Toxicol 2005; 18(6)946–953
- Henge-Napoli MH, Archimbaud M, Ansoborlo E, Metivier H, Gourmelon P. Efficacy of 3,4,3-LIHOPO for reducing the retention of uranium in rat after acute administration. Int J Radiat Biol 1995; 68(4)389–393
- Fukuda S, Ikeda M, Anzai K, Suzuki M, Katoh A, Kontoghiorghes GJ. Radiation protection by deferiprone in animal models. Hemoglobin 2006; 30(2)201–208
- Fukuda S, Iida H, Ikeda M, Yan X, Xie Y. Toxicity of uranium and the removal effects of CBMIDA and EHBP in simulated wounds of rats. Health Phys 2005; 89(1)81–89
- Fukuda S, Ikeda M, Nakamura M, Yan X, Xie Y. Effects of pH on DU intake and DU removal by CBMIDA and EHBP. Health Phys 2007; 92(1)10–14
- Henge-Napoli MH, Ansoborlo E, Chazei V, Houpert P, Paquest F, Gourmelon P. Efficacy of ethane-1-hydroxy-1,1-bisphosphonate (EHBP) for the decorporation of uranium after intramuscular contamination in rats. Int J Radiat Biol 1999; 75(11)1473–1477
- Martinez AB, Cabrini RL, Ubios AM. Orally administered ethane-1-hydroxy-1,1-bisphosphonate reduces the lethal effects of oral uranium poisoning. Health Phys 2000; 78(6)668–671
- Pashalidis L, Kontoghiorghes GJ. Effective complex formation in the interaction of 1,2-dimethyl-3-hydroxypyrid-4-one (Deferiprone or L1) with uranium (VI). J Radioanalytic Nuclear Chem 1999; 242(1)181–184
- Kontoghiorghes GJ, Pattichis K, Neocleous K, Kolnagou A. The design and development of deferipronr (L1) and other iron chelators for clinical use: targeting methods and application prospects. Curr Med Chem 2004; 11(16)2161–2183
- Kontoghiorghes GJ, Eracleous E, Economides C, Kolnagou A. Advanced in iron overload therapics. Prospects for effecive use of deferiprone (L1), deferoxamine, the new experimental chelators ICL670, GT56-252, L1NAII and their combinations. Curr Med Chem 2005; 12(23)2663–2681